The U.S. Food and Drug Administration (FDA) has approved prademagene zamikeracel (Zevaskyn) for the treatment of blistering ...

Zevaskyn won FDA approval upon Abeona’s second filing of a biologics license application (BLA) for the therapy.

Patients with severe dystrophic epidermolysis bullosa, or EB, have skin so fragile, the slightest touch can lead to ...

Scientists from MIT have discovered that the teenage years are the key window when acne-linked bacteria take hold on our ...

The FDA has approved Zevaskyn (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa, a rare genetic skin disorder.

Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S. revenue projected at $600 million.

The U.S. Food and Drug Administration (FDA) has approved Abeona Therapeutics Inc.’s ZEVASKYN gene-modified cellular sheets.

The U.S. Food and Drug Administration has approved Abeona Therapeutics' Zevaskyn (prademagene zamikeracel) for patients with ...

Abeona has won FDA approval for Zevaskyn, setting up a commercial challenge to Krystal Biotech in the rare skin disease ...

With FDA approval, Zevaskyn is set to be a game-changer in the treatment of recessive dystrophic epidermolysis ...

Patients with the debilitating dermatologic condition are born with COL7A1 mutations in both gene copies, affecting the ...

Barely a year after the U.S. FDA shackled Abeona Therapeutics Inc.’s cell-based gene therapy with a complete response letter, the agency has approved it for treating a rare and genetic skin disease.